HosenCare Brothers
VC Fund
HosenCare Brothers is a venture capital firm.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 20%
Last updated:
For AI agents: llms.txt
Industries HosenCare Brothers invests in
Stages HosenCare Brothers invests in
Countries HosenCare Brothers invests in
Investment Focus
Industry
- Biotechnology 4 (80%)
- Medical 1 (20%)
- Biopharma 1 (20%)
- Agriculture 1 (20%)
- Health Care 1 (20%)
Stage
- Seed 2 (40%)
- Series B 2 (40%)
- Series D 1 (20%)
Country
- China 4 (80%)
- United States 1 (20%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Wimi bio
|
Wimi Bio is a high-tech enterprise focusing on the innovative research and development of gene editing and biological breeding technologies. | Seed / Apr 25, 2023 | |
Weimai Medical
|
Weimai Medical is an all-inclusive resource for minimally invasive and non-invasive energy medicine solutions. | $14.3M / Seed / Sep 19, 2022 | |
InxMed
|
InxMed is a clinical-stage biotech company focusing on developing "Best-in-Disease Combination" medicines to bring novel treatment options for patients. Our innovations are inspired by patients and driven by an in-depth understanding of disease biology and pharmacology. InxMed is committed to building a translational platform equippedwith global-level top-notch know-how and efficient execution capabilities. | $50M / Series B / Mar 03, 2022 | |
Simcere Pharma
|
Founded on 28th March 1995, Simcere swiftly evolved from being a pure distributor of pharmaceutical products to become a leading manufacturer and supplier of drugs in China's rapidly growing pharmaceutical market. Simcere currently operates five GMP-certified manufacturing facilities, two nationwide sales and marketing subsidiaries, a researchand development center and manages over 4,000 employees. They are the first Chinese chemical and biological drug company to list on the New York Stock Exchange with IPO proceeds reaching US$ 261 million. | $93.8M / Series B / Jun 04, 2021 | |
Denovo Biopharma
|
Denovo Biopharma is a privately held biotech company providing a novel biomarker solution to personalize drug development. The core technology is the industry's first platform and algorithm to perform de novo genomic biomarker discovery retrospectively using archived clinical samples. This technology is especially useful for late stageclinical drugs that have completed trials with unsatisfactory efficacy. By identifying biomarkers correlated to patients' responsiveness to drug candidates retrospectively, our technology enables biotech and pharmaceutical companies to design new clinical trials in a targeted patient population to achieve significant efficacy and/or less adverse effects. Our platform can be broadly applied to biomarker discovery in many therapeutic areas, such as oncology, metabolic, cardiology, immunology and neurology. | $42.5M / Series D / Dec 10, 2020 |
Co-Investors
Jolmo Capital
2 deals together
Yingke Capital
2 deals together
AIHC Capital
1 deal together
China Resources Pharmaceutical Group
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does HosenCare Brothers invest in?
HosenCare Brothers invests primarily in Biotechnology, Medical and Biopharma startups, most often at Seed and Series B stage. Most of the 5 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did HosenCare Brothers last invest?
The most recent investment recorded for HosenCare Brothers closed in Apr 2023. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
